Voyager Therapeutics paused its preclinical Alzheimer's program targeting apolipoprotein E (APOE) expression, announced in its full-year earnings release.1
The APOE program was unveiled in July 2025, using a blood-brain-barrier-penetrant TRACER capsid to deliver a bifunctional payload reducing APOE4 and increasing APOE2 in mouse studies.1
The pause is to prioritize more advanced programs like tau-focused VY7523 (anti-tau antibody, phase 1 data expected H2 2026) and VY1706 (tau-silencing gene therapy, IND Q2 2026, dosing H2 2026); not due to negative data.13
Voyager has $201.7 million in cash extending into 2028 and reduced workforce by 30 employees in December 2025.13
Company focuses on tau as a key Alzheimer's target alongside amyloid, planning partnerships for later-stage development.12
Sources:
1. https://www.fiercebiotech.com/biotech/voyager-pauses-alzheimers-program-8-months-after-unveiling-asset
2. https://www.investing.com/news/transcripts/voyager-therapeutics-at-oppenheimer-conference-strategic-insights-on-alzheimers-93CH-4529906
3. https://marketchameleon.com/articles/b/2026/3/10/voyager-therapeutics-2025-results-cash-pipeline-partnerships